Product
ATG-019 + Niacin ER
1 clinical trial
2 indications
Indication
Solid TumorIndication
Non-Hodgkin lymphomaClinical trial
A Phase I Open-Label Study of the Safety and Tolerability of ATG-019, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaStatus: Terminated, Estimated PCD: 2023-10-02